2160GNI Group2160 info
$17.27info1.15%24h
Global rank8752
Market cap$820.34M
Change 7d11.05%
YTD Performance-11.47%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    GNI Group (2160) Stock Overview

    GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

    2160 Stock Information

    Symbol
    2160
    Address
    Nihonbashi-Honcho YS BuildingTokyo, 103-0023Japan
    Founded
    -
    Trading hours
    -
    Website
    https://www.gnipharma.com
    Country
    🇯🇵 Japan
    Phone Number
    81 3 6214 3600

    GNI Group (2160) Price Chart

    -
    Value:-

    GNI Group Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $17.27
    N/A
    Market Cap
    $820.34M
    N/A
    Shares Outstanding
    47.51M
    N/A
    Employees
    701.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org